Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Hershey Co — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while Hershey Co trades at $162.74 (market cap $32.66B). The key difference: Hershey Co is far larger — about 2.6× Halozyme Therapeutics Inc. Common Stock's market cap, and Hershey Co pays a 3.57% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Hershey Co for 135 Days on average.
| HALO | HSY | |
|---|---|---|
Market Cap | $12.58B | $32.66B |
Volume | 2,179,278 | 1,578,237 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $236.28 |
52-Week Low | $61.63 | $157.61 |
Typical Hold Time | 1 Days | 135 Days |
Enterprise Value | $14.49B | $37.79B |
Dividend Yield | — | 3.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Hershey (HSY) trades at $162.54, up 1.37% with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with 12.24% net margin and 32.81% ROE, though 2025 net income declined to $883M. Analyst consensus targets $204.62 with 65.72% hold ratings, while recent news highlights dividend resumption and international leadership changes.
HSY offers value near 52-week lows with 25% upside to consensus target, supported by consistent earnings outperformance and brand strength. Key risks include cocoa cost pressures, margin compression from 2025 results, and technical bearish momentum. The dividend yield of 3.57% provides income support during market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
